Back To Education Zone

touchCONGRESS Expert Opinions

Continuing the conversation with CDK4/6 inhibitors in advanced breast cancer from SABCS 2018

Menu

Introduction

Watch a series of internationally renowned clinical specialists from Europe and Japan discuss key clinical data of interest from the San Antonio Breast Cancer Symposium (SABCS) 2018 Congress, 3–8 December 2018.

The potential implications of these data for optimizing clinical outcomes for patients with advanced breast cancer are explored from both global and regional perspectives.

The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with breast cancer.

Learning Objectives

After watching these touchCONGRESS Expert Opinions from SABCS 2018, you should be able to:

  • Discuss key data of interest from SABCS 2018 in advanced breast cancer and what they may mean for local clinical practice.
  • Apply clinical trial evidence to inform sequencing of therapies and duration of treatment in patients with advanced breast cancer.
  • Review the identification of prognostic and differentiation factors to drive the optimal use of chemotherapy, endocrine therapy and combination therapy with targeted agents such as CDK4/6 inhibitors.

Please feedback on this touchCONGRESS Expert Opinions on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).